Search research articles
Contact Us
Filters
Showing results (41-50 of 70) with videos related to
Page
of 7
Sort By:
British Journal of Clinical Pharmacology
|
May 18, 2011
A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects
Hoai-Thu Thai, Christine Veyrat-Follet, Nicole Vivier, et al.
Statistical Methods in Medical Research
|
October 6, 2016
Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies
Caroline Petit, Adeline Samson, Satoshi Morita, et al.
Clinical Pharmacology and Therapeutics
|
August 23, 2025
Levofloxacin in Bone and Joint Infections: Development of an Application for Model-Informed Precision Dosing
Léo Mimram, Sophie Magreault, Florian Lemaitre, et al.
British Journal of Pharmacology
|
March 17, 2004
Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice
Sylvie Barraud de Lagerie, Emmanuelle Comets, Céline Gautrand, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
September 26, 2025
Population pharmacokinetics of mycophenolic acid and Bayesian estimator in lung transplant adults recipients in the early post-transplant period
Juliette Kauv, Séverine Feuillet, Aurélie Barrail-Tran, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
April 1, 2024
Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials
Marc Cerou, Hoai-Thu Thai, Laure Deyme, et al.
Clinical Pharmacokinetics
|
March 3, 2007
Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004
Karl Brendel, Céline Dartois, Emmanuelle Comets, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
January 29, 2026
Novel Drug-Disease Modeling Framework for Oncology Benefit-Risk Evaluation: Application to Tusamitamab Ravtansine
Marc Cerou, Christine Veyrat-Follet, Sophie Fliscounakis-Huynh, et al.
Clinical Pharmacology and Therapeutics
|
October 15, 2024
Longitudinal Analysis of Natural History Progression of Rare and Ultra-Rare Cerebellar Ataxias Using Item Response Theory
Alzahra Hamdan, Niels Hendrickx, Andrew C Hooker, et al.
BMC Medical Research Methodology
|
July 30, 2025
Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score
Niels Hendrickx, France Mentré, Alzahra Hamdan, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 70) with videos related to
Sort By:
Page
of 7
British Journal of Clinical Pharmacology
|
May 18, 2011
A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects
Hoai-Thu Thai, Christine Veyrat-Follet, Nicole Vivier, et al.
Statistical Methods in Medical Research
|
October 6, 2016
Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies
Caroline Petit, Adeline Samson, Satoshi Morita, et al.
Clinical Pharmacology and Therapeutics
|
August 23, 2025
Levofloxacin in Bone and Joint Infections: Development of an Application for Model-Informed Precision Dosing
Léo Mimram, Sophie Magreault, Florian Lemaitre, et al.
British Journal of Pharmacology
|
March 17, 2004
Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice
Sylvie Barraud de Lagerie, Emmanuelle Comets, Céline Gautrand, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
September 26, 2025
Population pharmacokinetics of mycophenolic acid and Bayesian estimator in lung transplant adults recipients in the early post-transplant period
Juliette Kauv, Séverine Feuillet, Aurélie Barrail-Tran, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
April 1, 2024
Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials
Marc Cerou, Hoai-Thu Thai, Laure Deyme, et al.
Clinical Pharmacokinetics
|
March 3, 2007
Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004
Karl Brendel, Céline Dartois, Emmanuelle Comets, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
January 29, 2026
Novel Drug-Disease Modeling Framework for Oncology Benefit-Risk Evaluation: Application to Tusamitamab Ravtansine
Marc Cerou, Christine Veyrat-Follet, Sophie Fliscounakis-Huynh, et al.
Clinical Pharmacology and Therapeutics
|
October 15, 2024
Longitudinal Analysis of Natural History Progression of Rare and Ultra-Rare Cerebellar Ataxias Using Item Response Theory
Alzahra Hamdan, Niels Hendrickx, Andrew C Hooker, et al.
BMC Medical Research Methodology
|
July 30, 2025
Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score
Niels Hendrickx, France Mentré, Alzahra Hamdan, et al.
Page
of 7